A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

PLINK: a tool set for whole-genome association and population-based linkage analyses.

Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089

Idiosyncratic drug hepatotoxicity

Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054

The genetics of multiple sclerosis: SNPs to pathways to pathogenesis

Oksenberg, J. R., Baranzini, S. E., Sawcer, S., & Hauser, S. L. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2395 · Cited by 347

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME

Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280

Case definition and phenotype standardization in drug-induced liver injury

Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., Hunt, C. M., Wilke, R. A., Avigan, M., Kaplowitz, N., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.58 · Cited by 944

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles

Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P., Andrade, R. J., Day, C. P., Ruiz–Cabello, F., Donaldson, P. T., Stephens, C., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.001 · Cited by 442

Drug-induced liver injury: recent advances in diagnosis and risk assessment

Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438

Mechanisms of drug-induced liver injury

Yuan, L., & Kaplowitz, N. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.002 · Cited by 322

Central role of mitochondria in drug-induced liver injury

Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

Topol, E. J., Bousser, M.-G., Fox, K. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60935-x · Cited by 266

CSH guidelines for the diagnosis and treatment of drug-induced liver injury

Drug-induced Liver Injury (DILI) Study Group, Yu, Y.-C., Chinese Society of Hepatology (CSH), Chinese Medical Association (CMA), Mao, Y.-M., Chen, C.-W., Chen, J.-J., Chen, J., Cong, W.-M., Ding, Y., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9793-2 · Cited by 254

Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study

Nicoletti, P., Aithal, G. P., Bjornsson, E. S., Andrade, R. J., Sawle, A., Arrese, M., Barnhart, H. X., Bondon-Guitton, E., Hayashi, P. H., Bessone, F., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.016 · Cited by 221

Genetics of primary sclerosing cholangitis and pathophysiological implications

Jiang, X., & Karlsen, T. H. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.154 · Cited by 155

HLA‐B*35:01 Allele Is a Potential Biomarker for Predicting Polygonum multiflorum–Induced Liver Injury in Humans

Li, C., Rao, T., Chen, X., Zou, Z., Wei, A., Tang, J., Xiong, P., Li, P., Jing, J., He, T., et al. (2019) · Hepatology · doi:10.1002/hep.30660 · Cited by 138

Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B *35:02 as a risk factor

Urban, T. J., Nicoletti, P., Chalasani, N., Serrano, J., Stolz, A., Daly, A. K., Aithal, G. P., Dillon, J., Navarro, V., Odin, J., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.010 · Cited by 124

Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis

Lucena, M. I., Kaplowitz, N., Hallal, H., Castiella, A., García-Bengoechea, M., Otazua, P., Berenguer, M., Fernandez, M. C., Planas, R., & Andrade, R. J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.12.041 · Cited by 89

Intrahepatic cholestasis in common chronic liver diseases

Jüngst, C., Berg, T., Cheng, J., Green, R. M., Jia, J., Mason, A. L., & Lammert, F. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12128 · Cited by 82

Human leukocyte antigen B∗14:01 and B∗35:01 are associated with trimethoprim-sulfamethoxazole induced liver injury

Li, Y., Phillips, E. J., Dellinger, A., Nicoletti, P., Schutte, R., Li, D., Ostrov, D. A., Fontana, R. J., Watkins, P. B., Stolz, A., et al. (2021) · Hepatology · doi:10.1002/hep.31258 · Cited by 76

The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment

Moreno-Torres, M., Quintás, G., & Castell, J. V. (2022) · Metabolites · doi:10.3390/metabo12060564 · Cited by 50

Next‐Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development

Roth, S. E., Avigan, M. I., Bourdet, D., Brott, D., Church, R., Dash, A., Keller, D., Sherratt, P., Watkins, P. B., Westcott‐Baker, L., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1571 · Cited by 42

Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design

Brink, A., Pähler, A., Funk, C., Schuler, F., & Schadt, S. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.018 · Cited by 42

Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status

Shi, Q., Yang, X., Greenhaw, J. J., Salminen, A. T., Russotti, G. M., & Salminen, W. F. (2017) · International Journal of Toxicology · doi:10.1177/1091581817721675 · Cited by 37

Genetic risk factors in the development of idiosyncratic drug-induced liver injury

Stephens, C., Lucena, M. I., & Andrade, R. J. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1854726 · Cited by 32

Ethnically diverse pluripotent stem cells for drug development

Fakunle, E. S., & Loring, J. F. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.10.007 · Cited by 27

The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?

Iruzubieta, P., Arias-Loste, M. T., Barbier-Torres, L., Martinez-Chantar, M. L., & Crespo, J. (2015) · BioMed Research International · doi:10.1155/2015/386186 · Cited by 24

Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis: the influence of human leucocyte antigen alleles

Stephens, C., Castiella, A., Gomez-Moreno, E. M., Otazua, P., López-Nevot, M.-Á., Zapata, E., Ortega-Alonso, A., Ruiz-Cabello, F., Medina-Cáliz, I., Robles-Díaz, M., et al. (2016) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000230 · Cited by 22

What have we learned from animal models of idiosyncratic, drug-induced liver injury?

Roth, R. A., & Ganey, P. E. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1760246 · Cited by 8

DILI Differences and Similarities between the US and Europe

Toro-Ortiz, J. P., Andrade, R. J., & Pinazo-Bandera, J. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00733-x